

FDA Approval Granted on New Titanium Dental Implant

Double-Strength Metal Expected to Integrate into Bone up to 20 Times Faster \$2 Billion Dental-Implant Market is Goal

December 9, 2008

Manhattan Scientifics (Pink Sheets:MHTX) today announced that its affiliated manufacturing partner in Albuquerque, N.M. has received Food and Drug Administration 510(k) clearance to market Manhattan Scientifics' super strong titanium metal dental implants. This clearance positions the company closer to its goal of commercializing its technology and increasing shareholder value.

The patented new form of titanium metal originally developed by Russian scientists in concert with scientists at the Los Alamos National Laboratory is expected to significantly improve dental implants. Studies have shown that bone integrates with these new metals up to 20 times faster than with conventional metals. Patients should experience shorter post surgery healing times and a more reliable integration of these new implants into their body.

Manhattan Scientifics Chief Scientist Terry Lowe said, "The \$2 billion annual dental implant wholesale market is 10% the size of the market for other medical devices (for example hips, spinal devices and cardiovascular stents) that can benefit from the advantages of our advanced metals."

The key manufacturers of dental implants include Nobel Biocare Holding AG (SWX:NOBN), Straumann Holding AG (SWX:STMN), Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH), DENTSPLY International, Inc. (NasdaqGS: XRAY), Biomet, Inc. and Thommen Medical AG.

Manhattan Scientifics anticipates developing additional products based on this new titanium metal for use in orthopedics and stents.

U.S. Food and Drug Administration - 510(k) Premarket Notification Database



About Manhattan Scientifics

Manhattan Scientifics, Inc., http://www.mhtx.com/, is located in New Mexico, New York, and Montreal. It is developing and plans to acquire technologies in a variety of environmentally friendly energy and other people-friendly industries. Copies of Manhattan Scientifics' press releases and related investor information may also be found at http://www.hawkassociates.com/.

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Executive Contacts:

Manny Tsoupanarias

Email: <u>mtsoupanarias@manhattan-scientifics.com</u>

Phone: 918-919-0370

Metallicum, Inc. - Dr. Terry Lowe Email: <u>tlowe@metallicum.com</u>

Phone: 505-670-8755

For Investor Relations contact MHTX Chairman Emeritus Marvin Maslow

Email: <u>marvin@marvinmaslow.com</u>

Phone: 917-923-3300

Media Contact:

Marvin Maslow, Chairman Emeritus

Tel.: (917) 923-3300.

Email: marvin@marvinmaslow.com

Institutional Investor Relations:

Frank Hawkins Hawk Associates

Tel: (305) 852-2383

Email: Fhawk@hawkassociates.com
Website: http://www.hawkassociates.com